Literature DB >> 15688370

Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma.

Jörg König1, Mark Hartel, Anne T Nies, Marc E Martignoni, Junchao Guo, Markus W Büchler, Helmut Friess, Dietrich Keppler.   

Abstract

Pancreatic ductal adenocarcinoma is among the top 10 causes of death from cancer in industrialized countries. In comparison with other gastrointestinal malignancies, pancreatic cancer is one of the tumors most resistant to chemotherapy. An important mechanism of tumor multidrug resistance is increased drug efflux mediated by several transporters of the ABC superfamily. Especially BCRP (ABCG2), MDR1 P-glycoprotein (ABCB1) and members of the MRP (ABCC) family are important in mediating drug resistance. The MRP family consists of 9 members (MRP1-MRP9) with MRP1-MRP6 being best characterized with respect to protein localization and substrate selectivity. Here, we quantified the mRNA expression of BCRP and of all MRP family members in normal human pancreas and pancreatic carcinoma and analyzed the mRNA level of the transporters most abundantly expressed in pancreatic tissue, BCRP, MRP1, MRP3, MRP4 and MRP5, in 37 tissue samples. In addition, we determined the localization of the 4 MRP proteins in normal human pancreas and in pancreatic carcinoma. The expression of BCRP, MRP1 and MRP4 mRNA did not correlate with tumor stage or grading. On the other hand, the expression of MRP3 mRNA was upregulated in pancreatic carcinoma samples and was correlated with tumor grading. The MRP5 mRNA level was significantly higher in pancreatic carcinoma tissue compared to normal pancreatic tissue. These data suggest that MRP3 and MRP5 are involved in drug resistance of pancreatic tumors and that quantitative analysis of their expression may contribute to predict the benefit of chemotherapy in patients with pancreatic cancer. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15688370     DOI: 10.1002/ijc.20831

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  53 in total

1.  Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome.

Authors:  Motofumi Tanaka; Taro Okazaki; Hideo Suzuki; James L Abbruzzese; Donghui Li
Journal:  Cancer       Date:  2010-10-04       Impact factor: 6.860

2.  Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine.

Authors:  Chong-Chong Gao; Xiao-Lan Xu; Fei Li; Ben-Gang Gong; Shuang Liu; Ye-Qing Cui; Hai-Chen Sun; Ping-Yong Xu; Ya-Min Zheng; Hua Jiang
Journal:  Tumour Biol       Date:  2015-12-18

3.  Blockade of Multidrug Resistance-Associated Proteins Aggravates Acute Pancreatitis and Blunts Atrial Natriuretic Factor's Beneficial Effect in Rats: Role of MRP4 (ABCC4).

Authors:  María Silvia Ventimiglia; Ana Clara Najenson; Juan Carlos Perazzo; Alejandro Carozzo; Marcelo S Vatta; Carlos A Davio; Liliana G Bianciotti
Journal:  Mol Med       Date:  2015-01-06       Impact factor: 6.354

4.  TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.

Authors:  Rachel A Hesler; Jennifer J Huang; Mark D Starr; Victoria M Treboschi; Alyssa G Bernanke; Andrew B Nixon; Shannon J McCall; Rebekah R White; Gerard C Blobe
Journal:  Carcinogenesis       Date:  2016-11-01       Impact factor: 4.944

5.  Armed and targeted measles virus for chemovirotherapy of pancreatic cancer.

Authors:  S Bossow; C Grossardt; A Temme; M F Leber; S Sawall; E P Rieber; R Cattaneo; C von Kalle; G Ungerechts
Journal:  Cancer Gene Ther       Date:  2011-06-24       Impact factor: 5.987

Review 6.  Multidrug resistance-associated proteins 3, 4, and 5.

Authors:  Piet Borst; Cornelia de Wolf; Koen van de Wetering
Journal:  Pflugers Arch       Date:  2006-04-04       Impact factor: 3.657

7.  hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations.

Authors:  F Wang; X Xue; J Wei; Y An; J Yao; H Cai; J Wu; C Dai; Z Qian; Z Xu; Y Miao
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

8.  Overexpression of ABCC3 promotes cell proliferation, drug resistance, and aerobic glycolysis and is associated with poor prognosis in urinary bladder cancer patients.

Authors:  Xuejun Liu; Dongwei Yao; Cheng Liu; Yunjian Cao; Qiurong Yang; Zhichao Sun; Duo Liu
Journal:  Tumour Biol       Date:  2016-01-05

9.  The transmembrane transporter ABCC3 participates in liver cancer progression and is a potential biomarker.

Authors:  Gabriela Carrasco-Torres; Samia Fattel-Fazenda; Guadalupe Soledad López-Alvarez; Rebeca García-Román; Saúl Villa-Treviño; Verónica Rocío Vásquez-Garzón
Journal:  Tumour Biol       Date:  2015-09-04

10.  MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells.

Authors:  Mark Eilers; Upal Roy; Debasis Mondal
Journal:  Exp Biol Med (Maywood)       Date:  2008-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.